The Potential of Mesenchymal Stromal Cell as Therapy in Neonatal Diseases

Frontiers in Pediatrics

article

Ling Ling Liau¹  Maimonah Eissa Al-Masawa²  Benson Koh²  Qi Hao Looi³  Jhi Biau Foo⁴  Sau Har Lee⁵  Fook Choe Cheah⁶  Jia Xian Law² 

[1] Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre;Centre for Tissue Engineering and Regenerative Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre;Future Cytohealth Sdn Bhd;School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University;School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University;Department of Paediatrics, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre

关键词: cell therapy;    clinical trial;    neonatal diseases;    extracellular vesicles;    mesenchymal stromal cells;   

DOI  :  10.3389/fped.2020.591693

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Mesenchymal stromal cells (MSCs) can be derived from various tissue sources, such as the bone marrow (BMSCs), adipose tissue (ADSCs), umbilical cord (UC-MSCs) and umbilical cord blood (UCB-MSCs). Clinical trials have been conducted to investigate the potential of MSCs in ameliorating neonatal diseases, including bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH) and necrotizing enterocolitis (NEC). In preclinical studies, MSC therapy has been tested for the treatment of various neonatal diseases affecting the heart, eye, gut, and brain as well as sepsis. Up to date, the number of clinical trials using MSCs to treat neonatal diseases is still limited. The data reported thus far positioned MSC therapy as safe with positive outcomes. However, most of these trials are still preliminary and generally smaller in scale. Larger trials with more appropriate controls and a longer follow-up period need to be conducted to prove the safety and efficacy of the therapy more conclusively. This review discusses the current application of MSCs in treating neonatal diseases, its mechanism of action and future direction of this novel therapy, including the potential of using MSC-derived extracellular vesicles instead of the cells to treat various clinical conditions in the newborn.

【 授权许可】

CC BY